SCYNEXIS Investor Relations Material
Latest events
Q1 2025
15 May, 2025
Q4 2024
12 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SCYNEXIS Inc
Access all reports
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SCYX
Country
🇺🇸 United States